Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients

Y Tanaka1, F Kanai, M Tada

  • 1Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Japan.

Oncogene
|December 7, 2005
PubMed

Insights

A study investigating PIK3CA hotspot mutations in Japanese hepatocellular carcinoma (HCC) found none. Unexpected sequences resembling a PIK3CA pseudogene were detected in both cancerous and non-cancerous tissues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene is frequently somatically mutated in various cancers.
  • PIK3CA mutations are reported in an estimated 35.6% of hepatocellular carcinoma (HCC) cases, suggesting its oncogenic role.

Purpose of the Study:

  • To determine the frequency of PIK3CA hotspot mutations in Japanese HCC patients.
  • To investigate unexpected findings during PIK3CA mutation analysis in HCC samples.

Main Methods:

  • Sequencing of exons 9 and 20 of the PIK3CA gene in 47 clinical HCC samples.
  • Analysis of PCR chromatograms for abnormal migration patterns.
  • PCR amplification, cloning, and sequencing to identify anomalous DNA sequences.

Main Results:

  • No PIK3CA hotspot mutations were detected in any of the 47 Japanese HCC samples.
  • Abnormally migrating waves in PCR chromatograms from 13 samples were identified as a mix of wild-type PIK3CA and a sequence from a PIK3CA pseudogene on chromosome 22q11.2.
  • These anomalies were also present in non-cancerous liver tissue, indicating they are not HCC-specific mutations.

Conclusions:

  • The frequency of PIK3CA hotspot mutations in Japanese HCC patients may be lower than previously reported.
  • The observed anomalies are likely due to the presence of a PIK3CA pseudogene, not somatic mutations driving HCC.
  • Further investigation is needed to clarify the role of PIK3CA alterations in HCC pathogenesis in this population.

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...